<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006006</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02347</org_study_id>
    <secondary_id>NYU-9938</secondary_id>
    <secondary_id>NCI-101</secondary_id>
    <secondary_id>CDR0000068014</secondary_id>
    <nct_id>NCT00006006</nct_id>
  </id_info>
  <brief_title>Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed</brief_title>
  <official_title>Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of thalidomide plus interferon alfa in treating&#xD;
      patients who have progressive liver cancer that cannot be surgically removed. Thalidomide may&#xD;
      stop the growth of liver cancer by stopping blood flow to the tumor. Interferon alfa may&#xD;
      interfere with the growth of the cancer cells. Combining thalidomide and interferon alfa may&#xD;
      kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility and activity of thalidomide in patients with unresectable&#xD;
      hepatocellular carcinoma.&#xD;
&#xD;
      II. Evaluate the toxicity of thalidomide in these patients. III. Assess the use of interferon&#xD;
      alfa in patients who develop disease progression while being treated with thalidomide.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at&#xD;
      least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously&#xD;
      twice daily. Treatment continues in the absence of disease progression after initiation of&#xD;
      interferon alfa therapy or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma OR&#xD;
&#xD;
          -  Diagnosis of hepatocellular carcinoma based on characteristic mass and&#xD;
             alpha-fetoprotein greater than 500 in the setting of known cirrhosis or chronic&#xD;
             hepatitis B or C&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 20 mm in one dimension&#xD;
&#xD;
          -  Not amenable to curative surgical resection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,200/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 mg/dL&#xD;
&#xD;
          -  Platelet count at least 25,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 5 mg/dL&#xD;
&#xD;
          -  Liver function tests no greater than 5 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Regardless of fertility status:&#xD;
&#xD;
               -  All women (unless they have undergone hysterectomy or have been amenorrheic or&#xD;
                  postmenopausal for at least 2 years) must use at least 1 highly active method of&#xD;
                  contraception AND 1 additional effective method of contraception at least 4 weeks&#xD;
                  before, during, and for at least 4 weeks after study&#xD;
&#xD;
               -  All men (even if they have undergone a successful vasectomy) must use effective&#xD;
                  barrier contraception during and for at least 4 weeks after study&#xD;
&#xD;
          -  No other medical condition that would preclude study&#xD;
&#xD;
          -  No other prior malignancy in past 5 years except curatively resected basal cell&#xD;
             carcinoma of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No more than 1 prior biologic therapy regimen&#xD;
&#xD;
          -  No prior interferon or thalidomide for hepatocellular cancer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent barbiturates or alcohol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew D. Volm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine's Kaplan Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005 Oct;10(9):718-27. doi: 10.1634/theoncologist.10-9-718.</citation>
    <PMID>16249352</PMID>
  </results_reference>
  <verification_date>September 2003</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

